Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 239-825-8 | CAS number: 15733-22-9
Absorption, distribution, excretion and metabolism, oral, rat (OECD 417):
absorption: the test material is mainly excreted via urine and thus it is absorbed to a high extent
distribution: no retention of compound related residues in organs or tissues of the animals
excretion: rapid excretion during the first 24 h after administration; completed after 7 days; mainly via urine
metabolism: 4 and 5 metabolites in urine of males and females, respectively; 4 metabolites in faeces of males and females, respectively
Accumulation in liver tisue and/or fatty tissue:
Liver tissue: no retention of compound related residues in the liver detected
Fatty tissue: occasionally values above the detection limit without relation to the dose or the time of exposure
Excretion in urine and faeces, metabolism in urine:
rapid excretion via urine mainly during the first 24 h after administration (67.2%); low excretion via faeces (0.40%); 2 highly polar metabolites detected in urine
There are no data available regarding toxicokinetic of sodium p-chloro-m-cresolate (CAS 15733-22-9). The assessment was therefore based on studies conducted with the analogue substance p-chloro-m-cresol (CAS 59-50-7) as part of a read across approach, which is in accordance with Regulation (EC) No 1907/2006, Annex XI, 1.5. Structural similarities and similarities in properties and/or activities of the source and target substance are the basis of read-across. A detailed justification for the analogue read-across approach is provided in the technical dossier (see IUCLID Section 13).
The toxicokinetic behavior (absorption, distribution, excretion) and metabolism of the source substance p-chloro-m-cresol was investigated in the Wistar HanRcc:WIST rat according to OECD Guideline 417 (1984) and in compliance with GLP (Rudolph, 2009). The test compound was radiolabelled with 14C in the phenol moiety of the molecule. A group of 4 male and 4 female rats received the test substance at a single dose of 300 mg/kg bw orally via gavage suspended in polyethylene glycol (PEG 400) as vehicle. The excretion of radioactivity in urine, faeces and expired air was measured in daily intervals up to 7 days after administration. The animals were sacrificed 7 days after dosing and residues of the test material were determined in selected organs and tissues. The metabolite pattern was investigated in urine and faeces extracts.
Between 121.48% and 119.46% of the administered dose were recovered from measurement of the total radioactivity in males and females, respectively. All mean values were normalized to a recovery of 100%. Rapid excretion mainly via urine was observed after oral administration. Within 24 h 85.21% and 84.30% of the administered dose was excreted in urine of male and female rats, respectively. During the same period of time 3.70% and 1.44% was excreted via faeces of male and female rats, respectively. The radioactivity excreted in the expired air was low (< 1% of the administered dose). Almost the complete administered dose was excreted after 7 days (99.03 and 98.94% in males and females, respectively). Less than 1% of the test material was detected in the remaining carcass and GI-tract. Extensive metabolism of the test material was identified in urine and faeces and excretion of respective metabolites was mainly via urine. The urinary metabolite pattern consisted of at least 5 metabolite fractions dominated by 2 major fractions (37-39% and 41-47% of the dose, respectively). Unchanged parent compound accounted for 4.97% and 11.35% of the administered dose in urine of males and females, respectively. In the fecal metabolite pattern the major fraction was found as unchanged parent compound (3-5% of the dose) while 4 metabolites in negligible amounts (< 1%) were detected in both sexes. The metabolite pattern was very similar for both sexes with some quantitative differences. Thus, under the conditions of this study, after oral administration of the radiolabeled test material to male and female Wistar rats, the recovery of radioactivity in urine, faeces, expired air and cage wash was almost complete. The radioactivity was mainly recovered in urine and to a lower extent in faeces but to a negligible extent in the expired air.
In a further study the potential of thesource substance p-chloro-m-cresolto accumulate in fatty tissue and /or liver tissue was investigated (Schmidt & Bomhard, 1981). Three groups of 12 male Wistar TNO/W74 rats received oral doses of 150, 500 or 1500 ppm of the test substance in the diet over 1, 4, 8 or 13 weeks. The liver as well as samples of fatty tissue from the abdominal cavity were removed from 3 animals per dose group 1, 4, 8 and 13 weeks after start of administration. The samples were homogenized and extracted with hexane before derivatisation with heptafluorobutyric acid anhydride for gas chromatography with electrochemical detection. Detectable concentrations of the test substance were not found in any of the liver samples (> 10 nmol/g). In the fatty tissue samples, concentrations of the test substance were occasionally above the detection limit of 4 nmol/g. No correlation was found between the applied dose and the amount of test substance in the samples. No cumulative effect was observed. Thus, under the conditions of the study, the test substance did not accumulate in liver and fatty tissues.
The excretion of the source substance p-chloro-m-cresolin urine and faeces of rats as well as the quantity of metabolites in urine was further assessed after single oral administration (Schmidt, 1980). Five male Wistar II rats received a single oral dose of 300 mg/kg bw via gavage and were housed individually in metabolism cages. Urine samples were taken at 4, 8, 24, 32, 48 and 72 hours after application and analysed by HPLC-UV. Faeces were collected at 24, 48 and 72 hours after application and measured by GC-ECD. In addition, the urine samples were analysed by TLC to identify potential metabolite. The major excretory route was via the urine with 67.2% recovery of the applied dose. The excretion was rapid within the first 24 h after application. Low concentrations were also detected up to 72 h. The faeces represent a minor excretory route, with only 0.40% recovery of the applied dose within 24 h post-dosing. Two highly polar metabolites were found in the urine samples after TLC analysis. Since these metabolites were not included in the calculation of the recovery they might be the explanation for the low recovery rate of around 68% and might account for the remaining 30%. Under the conditions of the study, the test substance is eliminated rapidly and extensively from the body; the urine was identified as the main way of excretion.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again